DDInter1793 DDInter1082
A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457)
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Thiethylperazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Magnesium carbonate
Thiethylperazine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sucralfate
Thiethylperazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sotalol
Thiethylperazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pregabalin
Thiethylperazine {u} may lead to a major life threatening interaction when taken with {v} Iohexol
Thiethylperazine {u} may lead to a major life threatening interaction when taken with {v} Tramadol
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate
Thiethylperazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Sotalol
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Pregabalin
Thiethylperazine may lead to a major life threatening interaction when taken with Iohexol
Thiethylperazine may lead to a major life threatening interaction when taken with Tramadol